Gaudium IVF IPO

Listed Mainboard
Open Feb 20
Close Feb 24
Allotment Feb 25
Refund Feb 26
Listing Feb 27

Market Sentiment

Grey Market Premium What is GMP?
Rs -4
-5.1%
Est. Listing: Rs 75
Updated: Feb 26, 2026 12:00 am
View Full GMP History →
Subscription Status
QIB
1.62x
NII
14.05x
bNII (>10L)
12.71x
sNII (2-10L)
16.73x
Retail
7.60x
Total
7.27x
Updated: Mar 02, 2026 10:51 pm IST
Analysis Score 41 / 100
Neutral
Data: 80%
GMP Score 20
Subscription Score 42
Financial Health 86
Score updates live as GMP/subscription change. For information only — not investment advice.

Market Lot Size

Category Lots Shares Amount (₹)
Retail Minimum 1 189 ₹14,931
Retail Maximum 13 2,457 ₹1,94,103
S-HNI Minimum 14 2,646 ₹2,09,034
S-HNI Maximum 66 12,474 ₹9,85,446
B-HNI Minimum 67 12,663 ₹10,00,377

IPO Details

Issue Price₹75-79 per equity share
Face Value₹5 Per Equity Share
Lot Size 189 shares (Min ₹14,931)
Total Issue Size ₹165.00 crore
Fresh Share₹90.00 crore
Offer For Sale₹75.00 crore
Issue TypeBook build Issue
Lead ManagerSarthi Capital Advisors Pvt. Ltd.
RegistrarBigshare Services Pvt. Ltd.
Listing atBoth
BSE Code544709
NSE SymbolGAUDIUMIVF
ISININE0P8B01020
Listing Price₹83.00
Listing Gain+5.06%

IPO Reservation

Category Shares Offered
QIB41,77,240
NII (HNI)31,32,930
bNII > ₹10L20,88,620
sNII < ₹10L10,44,310
Retail73,10,170
Anchor62,65,860

Financial Analysis

Financial Data
ROE
41.31%
ROCE
39.70%
Debt/Equity
0.41
NAV/Share
Rs 7.54
Revenue Growth
47.37%
Profit Margin
26.96%
Financial Performance
Metric 2023 2024 2025
Revenue 44.26 48.15 70.96
Expense 25.95 31.52 45.54
Profit (PAT) 13.53 10.32 19.13
Total Assets 36.63 51.01 88.51
Values in Crores (₹)
Promoters & Holding Pattern

Promoters: Dr. Manika Khanna, Dr. Peeyush Khanna and Vishad Khanna

Shareholding No. of Shares Holding %
Promoter Holding Pre Issue 6,13,94,384 99.99%
Promoter Holding Post Issue 7,27,86,884 71.30%

Company Information

About Gaudium IVF

Gaudium IVF, founded in March 2015, is one of the leading companies offering In Vitro Fertilization (IVF) treatments for women across India. The company operates its business over 30 locations, with seven hubs (centres) and twenty-eight spokes. The firm treats its patients in various countries, including Canada, the United Kingdom, the United States, Kenya, South Africa, and Oman. The firm offers various fertility services such as Vitro Fertilisation (IVF), intracytoplasmic sperm injection (ICSI), intrauterine insemination (IUI), and ovulation induction. Its treatments are targeted towards both genders. Moreover, the firm also provides PCOD/PCOS, endometriosis, and special care for women in pregnancy with complex fertility issues. Gaudium IVF also offers treatments targeting male infertility, including advanced sperm retrieval procedures.

Objects of the Issue
Purpose Amount (Cr)
Funding capital expenditure towards establishment of New IVF Centers of the Company 50.00
Repayment/pre-payment, in full or in part, of certain outstanding loans availed by our Company; and 20.00
General Corporate Purpose -

Resources & Documents

Anchor Investors
Anchor Bidding Date
February 19, 2026
Shares Offered to Anchors
62,65,860
Lock-in End (30 Days, 50%)
March 27, 2026
Lock-in End (90 Days, 50%)
May 26, 2026
Company Contact Information

Gaudium IVF & Women’s Health Ltd., B1/51,, Janak Puri,, B-1,, New Delhi, New Delhi, 110058

Gaudium IVF IPO — Quick Take

Gaudium IVF has set a price band of Rs 75–Rs 79 per share for an issue size of Rs 165 crore. The stock listed with a 5.06% gain versus its issue price on February 27, 2026.

Gaudium IVF, founded in March 2015, is one of the leading companies offering In Vitro Fertilization (IVF) treatments for women across India. The company operates its business over 30 locations, with seven hubs (centres) and twenty-eight spokes.

The issue is promoted by Dr. Manika Khanna, Dr. Peeyush Khanna and Vishad Khanna with Sarthi Capital Advisors Pvt. Ltd. acting as lead manager. Net proceeds will primarily be used towards Funding capital expenditure towards establishment of New IVF Centers of the Company (Rs 50 crore) and Repayment/pre-payment, in full or in part, of certain outstanding loans availed by our Company; and (Rs 20 crore).

Grey market is quoting a discount of Rs -4 (-5.1% over issue price), down Rs 4 from the previous session. Final subscription data records overall subscription at 7.27x, retail at 7.60x, QIB at 1.62x, NII at 14.05x.

On fundamentals, the company is posting revenue growth of 47.4%, a profit margin of 27.0%, return on equity of 41.3% in its most recent reported period.

Our data-driven engine currently flags this issue as a Neutral stance — the data is mixed and the risk-reward is balanced rather than one-sided. Past performance does not predict future returns — review the price chart and peer comparison below before trading.

Frequently Asked Questions

The price band of Gaudium IVF IPO is Rs 75 to Rs 79 per share. Face value is Rs 5 per share.

The total issue size of Gaudium IVF IPO is Rs 165 crore, comprising fresh issue of Rs 90 crore and offer for sale (OFS) of Rs 75 crore.

Retail investors must apply for a minimum of 1 lot of 189 shares, requiring an investment of Rs 14,931. Maximum retail application is 13 lots (2457 shares, approx Rs 1,94,103).

Gaudium IVF IPO opens for subscription on February 20, 2027 and closes on February 24, 2027. Anchor investor bidding is scheduled for February 19, 2026.

The expected allotment date for Gaudium IVF IPO is February 25, 2026. Refunds for unsuccessful applicants are expected on February 26, 2026.

Gaudium IVF IPO is scheduled to list on February 27, 2026 on both BSE and NSE. BSE script code: 544709, NSE symbol: GAUDIUMIVF, ISIN: INE0P8B01020.

The current GMP (Grey Market Premium) of Gaudium IVF IPO is Rs -4 (-5.1% over issue price). GMP is an unofficial grey market indicator and may change through the subscription window. See the GMP chart on this page for the full trend.

Gaudium IVF IPO is currently subscribed 7.27 times overall — retail at 7.60x, QIB at 1.62x, NII at 14.05x. Live subscription data updates multiple times per day on open-issue days.

Based on the current retail subscription of 7.60x for Gaudium IVF IPO, the estimated retail allotment probability is approximately 13.2%. This is a moderate probability of allotment.

The registrar for Gaudium IVF IPO is Bigshare Services Pvt. Ltd.. After the allotment date, you can check your allotment status on the registrar's official website by entering your PAN, application number, or demat account details. Allotment status is also available on the BSE and NSE websites.

The book running lead manager(s) for Gaudium IVF IPO are Sarthi Capital Advisors Pvt. Ltd..

The promoter(s) of Gaudium IVF are Dr. Manika Khanna, Dr. Peeyush Khanna and Vishad Khanna.

Understanding Grey Market Premium (GMP)

The Grey Market Premium (GMP) is an unofficial indicator of how an IPO's shares are trading in the grey market before they are officially listed on a stock exchange. It reflects investor sentiment and demand for the IPO shares ahead of listing day.

How does it work? The grey market is an informal, over-the-counter market where investors buy and sell IPO shares before the official listing date. If an IPO has a positive GMP, it suggests that investors expect the stock to list above its issue price. A negative GMP indicates expectations of a listing below the issue price.

Example: If an IPO has an issue price of ₹100 and the GMP is ₹50, the expected listing price would be approximately ₹150 (issue price + GMP). This translates to an estimated listing gain of 50%.

Factors that influence GMP:

  • Subscription levels — Higher subscription typically drives GMP up
  • Market conditions — Bullish markets tend to boost GMP across all IPOs
  • Company fundamentals — Strong financials and growth potential attract premium
  • Industry sentiment — Positive outlook for the sector can increase demand
  • IPO pricing — Reasonably priced IPOs relative to peers tend to command higher GMP

Disclaimer: GMP is an unofficial metric from the grey market and is not regulated by SEBI or any stock exchange. GMP values fluctuate frequently and should not be the sole basis for investment decisions. Always consider company fundamentals, financial health, and your own risk appetite before investing in any IPO.

0 Comments

No comments yet. Be the first to share your opinion!